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a b s t r a c t
Introduction: Human papillomavirus (HPV) vaccination has not been introduced in many countries in
South-Central Asia, including Afghanistan, despite the sub-region having the highest incidence rate of
cervical cancer in Asia. This study estimates the potential health impact and cost-effectiveness of HPV
vaccination in Afghanistan to inform national decision-making.
Method: An Excel-based static cohort model was used to estimate the lifetime costs and health outcomes
of vaccinating a single cohort of 9-year-old girls in the year 2018 with the bivalent HPV vaccine, com-
pared to no vaccination. We also explored a scenario with a catch-up campaign for girls aged 10–14 years.
Input parameters were based on local sources, published literature, or assumptions when no data was
available. The primary outcome measure was the discounted cost per disability-adjusted life-year
(DALY) averted, evaluated from both government and societal perspectives.
Results: Vaccinating a single cohort of 9-year-old girls against HPV in Afghanistan could avert 1718 cer-
vical cancer cases, 125 hospitalizations, and 1612 deaths over the lifetime of the cohort. The incremental
cost-effectiveness ratio was US$426 per DALY averted from the government perspective and US$400 per
DALY averted from the societal perspective. The estimated annual cost of the HPV vaccination program
(US$3,343,311) represents approximately 3.53% of the country0s total immunization budget for 2018
or 0.13% of total health expenditures.
Conclusion: In Afghanistan, HPV vaccine introduction targeting a single cohort is potentially cost-
effective (0.7 times the GDP per capita of $586) from both the government and societal perspective with
additional health benefits generated by a catch-up campaign, depending on the government0s willingness
to pay for the projected health outcomes.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cervical cancer is caused by the human papillomavirus (HPV).
More than 100 HPV types have been identified, about 40 of which
can infect the genital area. Two high-risk types of HPV, 16 and 18,
account for about 70% of all cervical cancer cases. Cervical cancer is
the second most common cancer in women living in lower-income
regions with an estimated 570,000 new cases and 311,000 deaths
annually [1–2]. While pre-cancerous cervical lesions and cervical
cancer are treatable if detected early, 85% of these deaths occur
in low- and middle-income countries (LMICs) where routine cervi-
cal cancer screening and treatment are not widely available. Across
Asia, age-standardized incidence rates vary from 4.4 to 19.3 per
100,000 person-years with South-Central Asia having the highest
incidence rate (19.3 per 100,00 person-years) of cervical cancer
across Asia [3–4]. In Afghanistan, for example, current estimates
indicate that 862 women are diagnosed with cervical cancer every
year and 570 die from the disease [5]. Afghanistan does not cur-
rently have a national screening program for cervical cancer [6],
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making primary prevention through vaccination particularly
important.
Since 2009, the World Health Organization (WHO) has recom-
mended vaccination as a primary prevention measure against cer-
vical cancer with a suggested target population of 9- to 14-year-old
girls [7]. Nonetheless, the vaccine has not yet been introduced in
many South-Central Asian countries, including Afghanistan. There
are currently three WHO-prequalified HPV vaccines available on
the market: a bivalent vaccine (Cervarix, produced by
GlaxoSmithKline) that protects against HPV types 16 and 18; a
quadrivalent vaccine (GARDASIL/Silgard, produced by Merck &
Co.) that protects against HPV types 16 and 18 as well as types 6
and 11, which are responsible for anogenital warts; and a nonava-
lent vaccine (Gardasil 9/Merck & Co.) that protects against types 6,
11, 16, 18, and the additional oncogenic types 31, 33, 45, 52, and 58
[8]. As of mid-2019, HPV vaccines have been introduced in 93
countries using a variety of delivery strategies including school-
based, health facility, and community-based programs [9].
Several studies suggest that HPV vaccination would be a cost-
effective intervention for the prevention of cervical cancer in most
countries [10,11]. However, to our knowledge, no data exists on
the potential health, financial, or economic impact of introducing
the vaccine in Afghanistan. Further, cost-effectiveness analyses of
vaccination in neighboring countries, such as Iran, India, China
and other countries in Central Asia, have provided mixed results
[12–15]. Individual country-level characteristics, local vaccine
pricing, and costs need to be considered to sufficiently inform gov-
ernments on the potential value of HPV vaccination.
Afghanistan benefits from financial support from Gavi, the Vac-
cine Alliance for introduction of new vaccines in the national
immunization program. There is an increasing need for the Afghan
government to develop a strong and robust evidence base for pub-
lic health priority-setting. Since 2002, Afghanistan primary health-
care services have been almost totally dependent on donor funding
to support the rebuilding of the health system following the col-
lapse of the Taliban regime. However, in recent years, the country
has experienced a drastic decrease in donor funding. In part to
address subsequently tighter budgets, the Ministry of Public
Health (MoPH) is in the process of critically appraising currently
funded health interventions and assessing the cost-effectiveness
of existing and future investments. Following that exercise, MoPH
will revise national healthcare investments to more efficiently
meet the health needs of the population under constrained
resources.
In 2016, in-country experts on immunization and rotavirus
disease undertook a study evaluating the health impact and
cost-effectiveness of rotavirus vaccination in Afghanistan. Study
results suggested good value for money with an incremental
cost-effectiveness ratio (ICER) of US$82 per disability-adjusted
life-year (DALY) averted. The projected average yearly cost of a
rotavirus vaccination program represented 2.8% of total immuniza-
tion costs expected in 2017 or 0.1% of total health expenditures
[16]. Subsequently, the country introduced rotavirus vaccine in
January 2018. To support the MoPH in identifying other high-
value vaccines for Afghan women and families, we conducted this
study to examine the potential health impact and cost-
effectiveness of introducing the HPV vaccine.
2. Methods
We compared the potential costs and health consequences of
HPV vaccination with no vaccination at the national level. A multi-
disciplinary team of experts from the National Immunization Advi-
sory Group (NITAG); the Health Economics and Financing
Directorate (HEFD); the Reproductive, Maternal, Neonatal, Child
and Adolescent Health Directorate (RMNCAH); the National
Expanded Program on Immunization (NEPI); the National Cancer
Control Program (NCCP); and the World Health Organization
(WHO) country office in Afghanistan carried out this study with
support of PATH and London School of Hygiene and Tropical Med-
icine (LSHTM). Considering the country context, vaccine price,
delivery costs, and licensed indications, the research team elected
to explore introduction of the bivalent vaccine, Cervarix
(GlaxoSmithKline Biologicals S.A.). The bivalent vaccine is a 2-
dose presentation [17] to be administered with at least six months
between the first and second dose.
In the analysis, our base-case scenario assumes a vaccination
target population of one cohort of girls aged 9 years old in the year
2018, relying on demographic projections (population size and life
expectancy by age, sex, and calendar year) over the lifetime of the
2009 birth cohort in Afghanistan [18]. We also assessed the mar-
ginal costs and benefits of including a one-time national catch-up
campaign of 10- to 14-year-old girls. The base-case scenario
reflects the lifetime costs and benefits of an ongoing vaccination
program, while the catch-up campaign scenario examines the
additional benefits and costs of vaccinating five additional cohorts
(10–14 years old) in the initial year. In short, the catch-up cam-
paign examines five additional cohorts (10–14 years old) in addi-
tion to the 9-year-old cohort.
This economic evaluation examines results from the govern-
ment perspective (vaccine program costs only) and the societal
perspective (vaccine program costs plus direct and indirect costs
of cervical cancer treatment) over the lifetime of the cohorts under
consideration. The primary outcome of the analysis is the cost per
disability-adjusted life-year (DALY) averted through vaccination.
Other outcomes include the number of cases, hospitalizations,
deaths, and treatment costs with and without vaccination, as well
as the incremental cost of the vaccination program.
3. Model
We used the UNIVAC decision-support model (version 1.4) for
the analysis. UNIVAC is an established static cohort model devel-
oped in Excel (Excel, Microsoft Corp, Redmond, WA, US) [19]. It
was specifically designed for use in LMICs by national health min-
istries and partners. It aims to produce conservative estimates of
impact and cost-effectiveness of new vaccine introduction to
inform national vaccine policy decisions. The model can be cus-
tomized to reflect the disease categories and age group(s) of inter-
est. Model input parameters include demographic data of the
target population, cervical cancer incidence and mortality by stage
(defined in the model as local, regional and distant), vaccine cover-
age and efficacy, costs of the vaccination program, and cervical
cancer treatment costs. The model is a simplified representation
of natural history of disease and does not incorporate progression
to or regression from different grades of cervical intraepithelial
neoplasia. Additionally, we assumed that no women receive cervi-
cal cancer screening to reflect the current practice in the country.
Data to inform inputs were gathered from the published literature,
published/unpublished local sources and local experts0 consulta-
tions, or based on assumptions when no information was available.
All model inputs were discussed by a multidisciplinary team of
experts led by an in-country lead researcher and a health econo-
mist from PATH. The expert team was consulted frequently
between April and October 2018 to achieve consensus on relevant
scenarios, identify appropriate data sources, and finalize input
parameters. All monetary terms were adjusted to 2018 US$ using
currency exchange rates from the central bank of Afghanistan
[20] (exchange rate at time of analysis: US$1 equals 73.5 Afghani
(AFN)) and the U.S. Consumer Price Index [21]. We applied a 3%
2 P. Anwari et al. / Vaccine xxx (xxxx) xxx
Please cite this article as: P. Anwari, F. Debellut, E. Vodicka et al., Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV)
vaccination in Afghanistan, Vaccine, https://doi.org/10.1016/j.vaccine.2019.12.013
discount rate for future costs and health outcomes in our calcula-
tions [22].
4. Disease burden
We used the United Nations Population Division (2017 revision)
database to estimate the size of the target population over time,
assuming a lifespan of 100 years [18]. Cervical cancer incidence
was estimated by 5-year age groups and stage of cancer (local,
regional, and distant). We used the Federation of International
Gynecology and Obstetrics (FIGO) classification for cervical cancer
to define local (stage IA, IIA, and IB1), regional (IB2, IIB, and IIIB),
and distant (IVB and IVA) stages [23]. Due to the absence of a
national cancer registry and local epidemiology studies, we used
international estimates to project the burden of cervical cancer in
Afghanistan based on GLOBOCAN, the global database from the
International Agency for Research on Cancer (IARC). GLOBOCAN
provides estimates of the incidence and mortality of major cancer
types by age group for 184 countries [21]. For Afghanistan, GLOBO-
CAN estimates an age-standardized rate of cervical cancer inci-
dence of 8.8 per 100,000 women per year and a mortality rate of
6.9 per 100,000. Age-specific GLOBOCAN rates used in our analysis
are shown in Table 1. We assumed there would be no change in
cancer incidence and mortality rates over time. For DALY calcula-
tions, we applied disability weights for cervical cancer of 0.288,
0.451, and 0.540 for local, regional, and distant cases, respectively,
based on the most recent Global Burden of Disease study data [24].
We also assumed an average duration of illness (i.e., time spent liv-
ing with disease) of 10, 7.5, and 2 years for local, regional, and dis-
tant cervical cancer, respectively, based on 5-year survival rates
from India and validated by in-country oncology experts [25].
5. Vaccine efficacy and coverage
The impact (% reduction) in cervical cancer cases and deaths fol-
lowing vaccine introduction was estimated to be 45%. This was cal-
culated by multiplying together (i) vaccine coverage, assumed to
be 70% of the target cohort (i.e. 9-year-old girls and (ii) vaccine
effectiveness (VE), assumed to be 65% after two doses. VE was esti-
mated by multiplying vaccine-type coverage, assumed to be 69%
based on the proportion of cervical cancer caused by types 16
and 18 in the Eastern Mediterranean region [26] by the efficacy
against types 16 and 18, assumed to be 94%. This is the mean of
the efficacy values reported in two pivotal trials (PATRICIA [27]
and FUTURE II HPV [28]. The efficacy of one-dose vaccination is still
uncertain; therefore, we made a conservative base case-
assumption that one dose of the vaccine (i.e., an incomplete
course) would confer half of the two-dose VE. Recent evidence sug-
gests that a single dose may confer similar VE as two doses so we
also ran a single-dose strategy with this assumption [29,30]. In
Table 1
Input parameters for estimating cervical cancer disease burden.
Parameters Estimate Source (s)
Age- Specific rates 100,000 per year, local cervical cancer cases
10–14 years old 0.00 [5]
15–19 years old 0.86
20–24 years old 0.86
25–29 years old 0.86
30–34 years old 0.86
35–39 years old 0.86
45–49 years old 5.02
50–54 years old 5.44
55–59 years old 0.09
60–64 years old 3.80
65–69 years old 2.85
70–74 years old 2.16
75–79 years old 1.46
80–84 years old 1.46
85–89 years old 1.46
90–94 years old 1.46
95–99 years old 1.46
Age-specific rates per 100,000 per year, regional cervical cancer cases
10–14 years old 0.00 [5]
15–19 years old 3.36
20–24 years old 3.36
25–29 years old 3.36
30–34 years old 3.36
35–39 years old 3.36
40–44 years old 15.94
45–49 years old 19.68
50–54 years old 21.32
55–59 years old 19.51
60–64 years old 14.88
65–69 years old 11.15
70–74 years old 8.46
75–79 years old 5.74
80–84 years old 5.74
85–89 years old 5.74
90–94 years old 5.74
95–99 years old 5.74
Age-specific rates per 100,000 per year, distant cervical cancer cases
10–14 years old 0.00 [5]
15–19 years old 0.39
20–24 years old 0.39
25–29 years old 0.39
(continued on next page)
P. Anwari et al. / Vaccine xxx (xxxx) xxx 3
Please cite this article as: P. Anwari, F. Debellut, E. Vodicka et al., Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV)
vaccination in Afghanistan, Vaccine, https://doi.org/10.1016/j.vaccine.2019.12.013
addition, we ran a scenario with the VE inflated to 40% for first dose
and 80% for the second dose to account for potential cross-
protection against non-vaccine types [31]. This scenario implies
48% efficacy after the second dose for the remaining 31% of cervical
cancer caused by types other than 16 and 18 in the Eastern
Mediterranean region [26]. Following vaccination, we assume
life-long protection [32].
Afghanistan, like many other low-resource countries, has used
mixed delivery strategies in national immunization programs to
achieve high vaccination coverage. Available delivery strategies
include fixed sites (e.g., health center), outreach (e.g., households
in the catchment area of a health facility), mobile (e.g., mobile
teams travel to remote and hard-to-reach geographical areas),
and campaigns (e.g., school and household). To reach girls 9 to
14 years of age, school-based delivery will likely be the primary
approach. We assumed 55% of the target population is in school
according to the school attendance rate for Afghan girls at the
age of 11 [33]. Forty-five percent of girls in the target population
will have to be reached differently, such as via health facilities or
community outreach activities. In consultation with the Expanded
Program on Immunization and other key stakeholders, we
assumed coverage rates of 70% and 65% for the first and second
dose, respectively (Table 2). For the catch-up campaign scenario,
we assumed an 80% and 75% coverage rate among girls aged
10–14 years for the first and second dose, respectively. Since some
of the girls in a catch-up campaign will be beyond the age of sexual
debut, we assumed the VE would be lower than the value assumed
for 9-year-old girls (55% vs 65%).
6. Health service utilization
Cervical cancer treatment options in Afghanistan are limited.
Only one public health facility–Jamhuryat Hospital in Kabul–pro-
vides more advanced treatment options. Jamhuryat Hospital has
a 60-bed tertiary care unit that provides basic diagnostic tests,
surgeries, and administration of chemotherapy medicines to a lim-
ited number of patients who are required to purchase their own
medicines outside of the hospital. Patients who can afford to seek
care typically do so in the private sector where they bear the entire
cost of treatment. Radiotherapy, one of the most effective treat-
ments for local and regional cervical cancer, is not available any-
where in the country. We assumed 15% of women referred to
radiotherapy would travel to India and Pakistan to seek these ser-
vices. In the absence of a screening program, cancer would only be
detected when women seek care for symptoms. We assumed that
1.74%, 7.35%, and 17.46% of local, regional, and distant cervical can-
cer cases, respectively, are detected symptomatically [34]. Annex 1
in supplementary file illustrates the typical set of activities
required to seek treatment for cervical cancer in Afghanistan.
Table 1 (continued)
Parameters Estimate Source (s)
Age- Specific rates 100,000 per year, local cervical cancer cases
30–34 years old 0.39
35–39 years old 0.39
40–44 years old 1.86
45–49 years old 2.30
50–54 years old 2.49
55–59 years old 2.28
60–64 years old 1.74
65–69 years old 1.30
70–74 years old 0.99
75–79 years old 0.67
80–84 years old 0.67
85–89 years old 0.67
90–94 years old 0.67
95–99 years old 0.67
Age-specific rates per 100,000 per year, cervical cancer deaths
10–14 years old 0.00 [5]
15–19 years old 1.51
20–24 years old 1.51
25–29 years old 1.51
30–34 years old 1.51
35–39 years old 1.51
40–44 years old 11.41
45–49 years old 17.93
50–54 years old 23.30
55–59 years old 25.49
60–64 years old 24.91
65–69 years old 23.23
70–74 years old 19.64
75–79 years old 14.76
80–84 years old 14.76
85–89 years old 14.76
90–94 years old 14.76
95–99 years old 14.76
Disability weights for DALY calculation
Disability weight (local) 0.288 [24]
Disability weight (regional) 0.451
Disability weight (distant) 0.540
Average number of years living with cervical cancer
Estimate Low High Source (s)
Local 10.00 7.50 15.00 Assumption based on expert consultation
Regional 7.50 5.00 10.00
Distant 2.00 1.00 3.00
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7. Healthcare costs
We estimated the direct medical, non-medical, and indirect
costs of cervical cancer diagnosis and treatment in private health
facilities. To estimate costs in the absence of data, we sought the
expert opinion of in-country clinicians and MoPH and NCCP offi-
cials. We used an ingredients-based method to estimate costs sep-
arately for local, regional, and distant cervical cancer. Direct
medical costs were based on established hospital fees for services.
We estimated non-medical costs accounting for accommodation,
food, and transportation costs incurred while seeking care. We also
calculated the indirect opportunity costs of seeking care for both
the female patient and her attendee. For each treatment strategy,
we estimated the number of days the pair would need to miss from
work or usual activities (e.g., taking care of children, leisure activ-
ities) due to diagnosis and treatment. We calculated costs associ-
ated with loss of productivity based on Afghanistan0s per capita
Gross Domestic Product (GDP), accounting for the number of days
lost. Input values are displayed in Table 3 and detailed calculations
for healthcare costs are available in Annex 2 in supplementary file.
8. Vaccination program costs
The last known vaccine price secured by Gavi for Cervarix is US
$4.60 per dose [17]. Afghanistan is eligible for Gavi support, falling
in the initial self-financing transition phase. In this transition
phase, country co-financing is US$0.20 per dose for routinely
administered vaccines [35–36]. Countries remain in this transition
phase as long as their per-capita Gross National Income (GNI)
remains below US$1045 [35]. For vaccines administered as a
catch-up campaign, Gavi would support HPV vaccines0 procure-
ment entirely [37]. In our base-case scenario, we use the country
co-financing rate and explore the impact of the country graduating
to pay the full vaccine price in an alternative scenario.
Due to the unavailability of country-level estimates for HPV
vaccination delivery, we used an average economic cost of US
$4.59 per dose based on the Immunization Costing Action Network
(ICAN) data reported by studies from five LMICs covering a mix of
vaccine delivery strategies [38]. In alternative scenarios, we
applied a lower delivery cost of US$1.73 per dose, as used previ-
ously by Campos et al. to model HPV vaccine impact in 50 LMICs
[39]. For the catch-up campaign we applied the lower delivery cost
of US$1.73 per dose, considering the campaign will reach a larger
group per vaccination session leading to a lower cost per dose
delivered.
We applied a wastage rate of 10% [40] and applied 3% and 4% of
the vaccine price to account for international handling and deliv-
ery, respectively [41]. We account for US$0.05 and US$0.01 per
dose for syringes and safety boxes, respectively [42] (Table 3).
9. Sensitivity analyses
We conducted univariate sensitivity analyses to identify the
impact of uncertainty introduced by individual study parameters
Table 2
Input parameters for estimating the health impact of HPV vaccination.
Parameter Estimate Scenarios Source (s)
Low High
Coverage in year of introduction
Dose 1 70% 55% 95% Assumption based on expert consultation
Dose 2 65% 50% 90%
Coverage in first year campaign
Dose 1 80% 55% 95% Assumption based on expert consultation
Dose 2 75% 50% 90%
Vaccine efficacy adjusted for vaccine types
After primary dose 1 32.50% – 65% [27,28]
After primary dose 2 65% – –
Vaccine cross-protection efficacy
After primary dose 1 40% [32]
After primary dose 2 80%
Table 3
Input parameters for estimating health service utilization, health service cost and vaccine program cost (all costs are presented in 2018 US$).
Parameter Estimate Scenarios Source (s)
Low High
Treatment seeking proportion (identified via symptoms)
Local 1.74% 0.87% 3.48% [34]
Regional 7.35% 3.675% 14.7%
Distant 17.46% 8.73% 34.92%
Health service cost
Household cost per treated woman
Local cancer $4,816.18 $3,315.71 $6,273.11 Cost calculations see Annex 1
Regional cancer $5,715.62 $4,215.15 $8,060.68
Distant cancer $5,132.13 $5,132.13 $6,616.32
Vaccine program cost
Vaccine price per dose (routine) $0.20 – $4.60 [17,35,36]
Vaccine price per dose (campaign) $0.0 – $4.60 [37]
Percentage of international handling 3.0% – – [41]
Percentage of international delivery 4.0% 2.0% 6.0%
Percentage of wastage 10.0% – – [40]
Cost of syringes (price per dose) $0.05 – - [42]
Safety box (price per dose) $0.01 – –
Incremental health system cost (routine) $4.59 $1.73 $6.32 [38,46]
Incremental health system cost (campaign) $1.73 – –
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on model outcomes. We conducted additional sensitivity analyses
to model variations in vaccine price, health service utilization,
healthcare treatment costs, incremental health system costs, vac-
cine coverage, and vaccine efficacy.
10. Results
10.1. Base-case scenario
The UNIVAC model estimated that, without vaccination, 4026
cervical cancer cases, 281 hospitalizations, 3678 deaths, and
17,919 DALYs would occur in the lifetime of a single cohort of girls
aged 9 years old. Introducing HPV vaccine targeting a single cohort
of 9-year-olds without a catch-up campaign is projected to avert
1765 cervical cancer cases, 123 hospitalizations, 1612 deaths,
and 7855 DALYs for a single year of vaccination. When the model
was extended to include a catch-up campaign for additional
cohorts of girls 10–14 years old, we projected that, in the absence
of a vaccination program, there would be 19,569 cases, 1365 hos-
pitalizations, 17,865 deaths, and 92,062 DALYs due to cervical can-
cer. In the 9- to 14-year-old targeted population, HPV vaccination
would subsequently avert 9849 cases, 687 hospitalizations, 8991
deaths, and 46,332 DALYs. Table 4 provides the total number of
cases, hospitalizations, deaths, and DALYs projected to occur with
and without HPV vaccination under each scenario.
We estimate it would cost the government US$3,343,311 per
year (3.53% of country0s total immunization budget for 2018) to
vaccinate a single cohort of 9-year-old girls without a catch-up
campaign and US$9,249,429 (9.76% of country0s total immuniza-
tion budget for 2018) to vaccinate a cohort of 9-year-old girls with
a catch-up campaign in the additional cohorts. HPV vaccination
would prevent US$203,226 healthcare costs related to downstream
cervical cancer treatment for one cohort of girls immunized or US
$1,202,566 with the addition of a catch-up campaign in the addi-
tional cohorts, 10–14 years old (Table 5).
Overall, we estimated that from the government perspective,
HPV vaccination in Afghanistan would yield an ICER of US$426
(72.7% of GDP per capita) and US$200 (34.13% of GDP per capita)
per DALY averted for a single cohort without and with a catch-up
campaign, respectively. From the societal perspective, the ICER
suggests that HPV vaccination would cost US$400 (68.3% of GDP
per capita) and US$174 (29.7% of GDP per capita) per DALY averted
for a single cohort without and with a catch-up campaign,
respectively.
11. Sensitivity analysis
Results of the sensitivity analysis for HPV vaccination of 9-year-
old girls showed that the estimated ICER ranged from US$180 to US
$876 (0.3 to 1.5 times Afghanistan0s GDP per capita) from the gov-
ernment perspective. Table 6 details the values associated with
parameter value changes. Scenarios applying high health system
costs with co-financing and the full price of the vaccine resulted
in higher ICERs of US$575 and US$867 (1–1.5 times GDP), respec-
tively. From the societal perspective, the estimated ICER ranged
from US$154 to US$850 (0.26 to 1.45 times GDP per capita)
(Fig. 1). Similar uncertainty analyses were run for vaccination of
9-year-old girls with a catch-up campaign of 10- to 14-year-old
girls. Results were similar with a cost per DALY averted ranging
from US$152 to US$287 from the government perspective
(0.25 to 0.49 times GDP per capita) and from US$126 to US$261
(0.22–0.45 times GDP per capita) from the societal perspective.
The lowest ICERs were found when applying low incremental
health system costs (Fig. 2).
We also examined scenarios for higher vaccine efficacy,
accounting for cross-protection against other types of HPV in addi-
tion to types 16 and 18. Results showed that ICERs decreased to US
$346 and US$320 from the government and societal perspectives,
respectively, in a single cohort of adolescent girls. When we exam-
ined cross-protection among 9-year-old girls with a catch-up cam-
paign of five additional cohorts of girls, the cost per DALY averted
decreased further to US$162 and US$136 from the government and
societal perspectives. Finally, when we assumed a single dose of
HPV vaccine would yield equivalent efficacy to a two-dose HPV
vaccine schedule, the ICER decreased to one-third and one-fourth
of the GDP per capita for a single cohort and a single cohort with
a catch-up campaign with costs per DALY averted of US$146 and
US$100, respectively. Results from the univariate sensitivity analy-
ses indicate that introduction of HPV vaccination would likely be
cost-effective from both the government and societal perspectives
with additional benefits of adding a catch-up campaign of 10- to
14-year-old girls. Main model drivers include the vaccine price
and the incremental health system costs.
12. Discussion
This analysis suggests that in Afghanistan, introduction of the
bivalent HPV vaccine is likely cost-effective compared to no
Table 4
Lifetime health outcomes of HPV vaccination of a single cohort of 9-year-old girls
with and without an initial catch-up campaign among 10- to 14-year-old girls.
Single cohort of 9-year-old girls without catch-up campaign
No vaccine With vaccine Averted
Total cervical cancer cases 4,026 2,261 1,765
Local cancer 749 420 328
Regional cancer 2,934 1,648 1,286
Distant cancer 343 193 150
Total cervical cancer Hospital visits 281 158 123
Local cancer 14 8 6
Regional cancer 216 121 95
Distant cancer 51 29 23
Deaths 3,678 2,066 1,612
DALYS (Discounted) 17,919 10,065 7,855
Single cohort of 9-year-old girls with catch-up campaign in additional five cohorts
(10- to 14-year-old girls)
No vaccine With vaccine Averted
Total cervical cancer cases 19,569 9721 9849
Local cancer 3639 1807 1831
Regional cancer 14,264 7085 7178
Distant cancer 1,667 828 839
Total cervical cancer Hospital visits 1365 678 687
Local cancer 67 34 34
Regional cancer 1048 521 528
Distant cancer 249 124 125
Deaths 17,865 8874 8991
DALYS (Discounted) 92,062 45,730 46,332
Table 5
Discounted lifetime costs of HPV vaccination of single cohort of girls 9-year-old girls
with and without an initial catch-up campaign among 10- to 14-year-old girls.
Single cohort of 9-year-old girls without catch-up campaign
No
vaccine
HPV
vaccine
Delta
Total government healthcare cost – – –
Total societal healthcare costs 463,633 260,407 203,226
Total vaccine program cost
(government perspective)
– 3,343,311 –
Single cohort of 9-year-old girls with catch-up campaign in additional five cohorts
(10- to 14-year-old girls)
Total government healthcare cost – – –
Total societal healthcare costs 2,391,556 1,188,989 1,202,566
Total vaccine program cost
(government perspective)
– 9,249,429 –
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Table 6
Parameters and values utilized in sensitivity analyses.
Scenario Parameter Base value Sensitivity value Source
Full vaccine price Vaccine price per dose $0.20 $4.60 [17]
Low treatment seeking Treatment seeking proportion [34]
Local 1.74% 0.87%
Regional 7.35% 3.675%
Distant 17.46% 8.73%
High treatment seeking Treatment seeking proportion [34]
Local 1.74% 3.48%
Regional 7.35% 14.7%
Distant 17.46% 34.92%
Low health system costs Incremental health system cost (routine) $4.59 $1.73 [38,46]
High health system costs Incremental health system cost (routine) $4.59 $6.32 [38,46]
Low vaccine coverage Coverage in year of introduction Assumption based on expert consultation
Dose 1 70% 55%
Dose 2 65% 50%
Coverage in first year campaign
Dose 1 80% 55%
Dose 2 75% 50%
High vaccine coverage Coverage in year of introduction
Dose 1 70% 95%
Dose 2 65% 90%
Coverage in first year campaign
Dose 1 80% 95%
Dose 2 75% 90%
Low healthcare costs Household cost per treated woman Cost calculations see Annex 1
Local cancer $4,816.18 $3,315.71
Regional cancer $5,715.62 $4,215.15
Distant cancer $5,132.13 $5,132.13
High healthcare costs Household cost per treated woman Cost calculations see Annex 1
Local cancer $4,816.18 $6,273.11
Regional cancer $5,715.62 $8,060.68
Distant cancer $5,132.13 $6,616.32
1 dose = 2 dose efficacy Efficacy after primary dose 1 32.5% 65% [27,28]
Cross protection Efficacy after primary dose 2 65% 80% [32]
Fig. 1. Sensitivity analysis for single cohort of girls aged 9 years old, 2018a aThe figure show the incremental cost-effectiveness ratio for each scenario evaluated. The light
gray bars show ICER from the government perspective, the dark grey bars show ICER from the societal perspective. The dotted line shows the cost-effectiveness threshold of
one times GDP per capita.
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vaccination based on an established local willingness-to-pay
threshold of one times the GDP per capita of US$586. ICERs ranged
from US$426 (0.73 times GDP per capita) to US$200 (0.34 times
GDP per capita) without and with a catch-up campaign, respec-
tively, from the government perspective and US$400 and US$174
(0.68 and 0.30 times GDP per capita), respectively, from the soci-
etal perspective. The annual cost to implement an HPV vaccination
program in routine vaccination only or with a catch-up campaign
would represent approximately 3.53% or 9.76% of the country0s
total immunization budget for 2018, or 0.13% and 0.35% of total
health expenditures, respectively.
Drivers of the results are mainly the vaccine price and the incre-
mental health system cost. This finding confirms results from other
cost-effectiveness studies in the region, which suggest that a low
vaccine price and cost per vaccinated girl are critical to achieving
good value for money. For example, a cost-effectiveness analysis
in Iran, an upper middle income country where the expected vac-
cine price is higher at approximately US$13–16, the vaccine was
not found to be cost-effective when compared to a threshold of
GDP per capita (US$14,289 in 2015) [12]. Contrasting results from
India, a lower-middle income country with Gavi pricing, projected
the vaccine to be very cost effective with an incremental cost per
quality-adjusted life year gained of INR 73 or US$1.12 compared
to a willingness to pay threshold of INR 10,000 or US$135 in
2016. An evaluation of Eastern European and Central Asian coun-
tries, including Afghanistan0s neighboring countries of Turk-
menistan, Uzbekistan, and Tajikistan, found that cost per
vaccinated girl was the key driver of cost-effectiveness [15]. While
the cost of vaccine procurement is set by Gavi0s co-financing policy
for qualifying countries, there is an incentive to minimize the cost
to deliver the vaccine as much as possible by finding the correct
strategy to reach girls. Further, for long-term sustainability of an
HPV vaccination program, vaccine price setting needs to be achiev-
able for countries that have graduated from Gavi eligibility but still
may not be able to afford higher prices provided to countries that
no longer qualify for UNICEF pricing. Single-dose vaccination may
be a more attractive scenario economically, but more research on
the long-term efficacy is required prior to adoption of such a strat-
egy. HPV vaccination could have a profound positive impact on the
long-term health outcomes of girls and women in Afghanistan,
particularly given that cervical cancer screening is currently not
available in the country and treatment services are limited. Addi-
tionally, families bear all healthcare costs out of pocket, making
access to cervical cancer care out of reach for many women and
their families. These health systems challenges are compounded
by rapid demographic and epidemiologic transitions that have
led South and Central Asian countries, including Afghanistan, to
experience an increasing health burden of non-communicable dis-
eases [43]. IARC estimated there were 20,000 cases of any type of
cancer in Afghanistan in 2012. By 2030, this figure is expected to
rise by 61% (almost 33,000) [44]. Cervical cancer is unique in that
it is preventable, detectable, and treatable if addressed effectively.
Tools for doing so have widely been accepted as cost-effective;
however, incidence rates in many countries, including Afghanistan,
continue to be unacceptably high, prompting WHO to call for glo-
bal elimination of cervical cancer [45]. To support countries in
addressing this call to action, evidence is needed to identify opti-
mal and affordable strategies for a national approach. This study
provides evidence regarding the potential health and economic
impact of initiating HPV vaccination to reduce the burden of cervi-
cal cancer in Afghanistan.
The decision to introduce newer vaccines, such as rotavirus,
pneumococcal, and HPV vaccines, requires careful attention
toward affordability and cost-effectiveness due to their higher
Fig. 2. Sensitivity analysis for single cohort of girls aged 9 years old with catch-up campaign of 10- to 14-year-old girls, 2018a.a The figure show the incremental cost-
effectiveness ratio for each scenario evaluated. The light gray bars show ICER from the government perspective, the dark grey bars show ICER from the societal perspective.
The dotted line shows the cost-effectiveness threshold of one times GDP per capita.
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costs compared to earlier antigens. In 2017, Afghanistan conducted
a cost-effectiveness analysis using the UNIVAC model exploring
rotavirus vaccine introduction strategies [16]. Findings of that eco-
nomic evaluation indicated that introduction of rotavirus vaccine
compared to no vaccine was likely to be highly cost-effective based
on a willingness-to-pay threshold of one times the GDP per capita
(US$562). That study helped policymakers in Afghanistan make an
informed decision on whether to include rotavirus vaccine in the
national immunization program, which was operationalized in Jan-
uary 2018. Building off this success, we applied the same method-
ological strategy to evaluate the cost-effectiveness of HPV
vaccination to provide similar decision support to the Government
of Afghanistan. Similar to rotavirus vaccine, the potential budget
impact of introducing HPV vaccination appears substantial despite
financial support available from Gavi, while achievable health
gains are projected to be lower. Vaccination program investments
will need to be weighed against other health investment priorities
for the MoPH.
This study has a number of limitations. First, we were not able
to include the potential health and costs associated with other pre-
ventive interventions, such as screening or treatment for precan-
cerous lesions. However, in an evaluation of the health and
economic impact of scaling cervical cancer prevention in 50 low-
and lower-middle-income countries, including Afghanistan, Cam-
pos et. al. found that a combined strategy of HPV vaccination of
young girls with a cervical cancer screen-and-treat program could
avert substantial burden of disease while providing good value for
public health dollars [46]. Second, burden of disease data were not
available for Afghanistan. Rather, we used GLOBOCAN estimates
for age-specific incidence of cervical cancer based on a mean inci-
dence in Afghanistan0s neighboring countries, Pakistan and Tajik-
istan, which could underestimate or overestimate the real burden
of disease [5]. A nationwide comprehensive cancer registry would
support future cancer-related decision-making in Afghanistan.
Third, there were no data on healthcare-seeking behavior among
cervical cancer patients and access to treatment facilities. Thus,
we relied on estimates from the literature and varied parameters
via sensitivity analysis. Fourth, HPV vaccine is targeting a popula-
tion that is not routinely served under the current national immu-
nization schedule. Based on in-country consultation and available
literature, we made assumptions for vaccine coverage and esti-
mated incremental health system costs associated with introduc-
ing HPV vaccine. We relied on published data in the absence of
local empiric data. The incremental health system cost per dose
applied in the study is relatively high (US$4.59) and sensitivity
analysis showed that this parameter is a driver of results. Should
Afghanistan manage to deliver HPV vaccine at a lower system cost,
the value for money of HPV vaccination would substantially
increase. The costs of treatment of cervical cancer estimated in this
study are higher than that of other LMICs presented in the pub-
lished literature [46]. Non-medical costs comprised a large portion
(28% to 31%) of total treatment costs by stage, primarily driven by
assumed costs of traveling abroad to receive radiotherapy services.
However, our estimates were close to those from other published
studies. For instance, treatment costs of local and regional/distant
cancer were reported to be US$4492 and US$5387, respectively, in
El Salvador [47], which are close to our health care cost estimates.
To account for uncertainties in our input data, we conduct sensitiv-
ity analyses. However, our results do not include uncertainty inter-
vals and the sensitivity analyses provide useful but incomplete
results under uncertainty. Finally, our results should be viewed
as conservative as we do not account for herd protection and our
analysis excludes reductions in other HPV-related cancers.
The use of GDP-based cost-effectiveness thresholds (CETs) as a
benchmark for whether the health gains offered by an intervention
are large enough to justify any additional costs as recommended by
the Commission on Macroeconomics in Health has recently been
challenged [48,49]. WHO updated these recommendations calling
for countries to establish their own specific willingness-to-pay
thresholds, taking into consideration factors such as affordability
and feasibility [50]. Woods et al. predicted CET values for a list of
LMICs and, according to their study, for Afghanistan CET would
range from US$19 to US$349 [51]. However, the local expert team
in Afghanistan elected to use one times the GDP per capita ($586)
as a threshold for cost-effectiveness and a proxy of the govern-
ment0s willingness to pay, in line with the country0s current prac-
tice for such evaluation.
As there are no organized screening and treatment options
available in the country, HPV vaccination should receive additional
consideration as a way to reduce cervical cancer burden in the
country. Investing in women0s health through prevention of cervi-
cal cancer and other diseases can have positive effects that extend
beyond the health costs and consequences included in this analy-
sis, such as downstream impact on mental health, education, and
economic status of family members. These and other non-
healthcare sector costs were not included in our analysis but war-
rant consideration when evaluating the potential impact of pre-
venting HPV morbidity and mortality among women in
Afghanistan [52].
13. Conclusion
In Afghanistan, introduction of HPV vaccine is likely to be cost-
effective compared to no vaccine according to the local
willingness-to-pay threshold of one times the GDP per capita of
US$586. Incremental cost-effectiveness ratios for HPV vaccination
with the bivalent vaccine are projected to be US$426 and US$200
per DALY averted without and with a catch-up campaign, respec-
tively, from the government perspective, and US$400 and US$174
per DALY averted from the societal perspective. In all scenario
explored, including a catch-up campaign with the introduction of
routine HPV immunization was more cost-effective than routine
immunization alone. In addition to reducing burden on the health
system, preventing downstream disease would reduce the finan-
cial and economic shocks imposed on women and their families.
Importantly, cost-effectiveness estimates need to be considered
in tandem with vaccination program affordability and feasibility
for the government.
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